EUVIMEDOpdag EUVIMED
Crossref

FDA Approval of Respiratory Biosimilars—Turning the Tide of Cost‐Effectiveness?

Ashley L Miller, Charles A Elmaraghy, Casey D Curtis, Vinay K Rathi

Otolaryngology–Head and Neck Surgery · 2026

DOI: 10.1002/ohn.70227 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2026. Written by Ashley L Miller and 3 co-authors. Institution: Department of Otolaryngology, Nationwide Children's Hospital, Columbus, Ohio, USA. Major MEDLINE topics: Biosimilar Pharmaceuticals, Cost-Effectiveness Analysis, Drug Approval, Nasal Polyps. Cited 1 times so far (Crossref); 10 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

In March 2025, the Food and Drug Administration (FDA) approved the first respiratory biosimilar: omalizumab‐igec. FDA designated omalizumab‐igec as “interchangeable” with the anti‐IgE antibody omalizumab, which will permit pharmacists to perform substitution without consulting providers. This biosimilar will compete with blockbuster biologics indicated for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) and other inflammatory airway diseases. Biologics are presently not cost‐effective for CRSwNP and should be reserved for patients who have not responded to conventional therapy (eg, nasal steroids and endoscopic sinus surgery) or are unfit for surgery. However, market entry of omalizumab‐igec and other omalizumab biosimilars in late‐stage clinical development may spur substantial price reductions if biosimilar manufacturers are able to overcome barriers such as patient and physician skepticism and restrictive state pharmacy laws (eg, requiring patient consent for biosimilar substitution). Comparative cost‐effectiveness research is necessary to inform coverage policies and treatment decisions by patients and clinicians.

Subjects

MeSH terms (MEDLINE)

Biosimilar PharmaceuticalsCost-Effectiveness AnalysisDrug ApprovalNasal PolypsOmalizumabSinusitisHumansChronic DiseaseCost-Benefit AnalysisRhinosinusitisUnited StatesUnited States Food and Drug Administration

Author keywords

FDAallergyasthmabiologicbiosimilarchronic sinusitiscost‐effectivenessnasal polypsomalizumabomalizumab‐igec

Substances

Biosimilar PharmaceuticalsOmalizumab

Authors and institutions

  • Department of Otolaryngology, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Otolaryngology-Head & Neck Surgery, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Department of Otolaryngology-Head & Neck Surgery, Division of Allergy and Immunology, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • The Center for the Advancement of Team Science, Analytics, and Systems Thinking in Health Services and Implementation Science Research (CATALYST), The Ohio State University College of Medicine, Columbus, Ohio, USA.

Cite

APA

Miller, A. L., Elmaraghy, C. A., Curtis, C. D., & Rathi, V. K. (2026). FDA Approval of Respiratory Biosimilars—Turning the Tide of Cost‐Effectiveness?. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70227

Vancouver

Miller AL, Elmaraghy CA, Curtis CD, Rathi VK. FDA Approval of Respiratory Biosimilars—Turning the Tide of Cost‐Effectiveness?. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70227

BibTeX
@article{Miller2026,
  author = {Miller, Ashley L and Elmaraghy, Charles A and Curtis, Casey D and Rathi, Vinay K},
  title = {FDA Approval of Respiratory Biosimilars—Turning the Tide of Cost‐Effectiveness?},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70227}
}
Start for free →